Pfizer shoots for a high price with tafamidis
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
Leviticus Cardio charges towards the market
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
ACC 2019 – Low risk of patients being denied transcatheter aortic valves
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
ACC 2019 – Anacetrapib analysis throws doubt on Dalcor play
No genetic correlation was seen with Merck & Co's CETP inhibitor, but Dalcor believes that things will be different for dalcetrapib.
ACC 2019 round-up – Esperion and Amarin prepare to go it alone
As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
ACC 2019 preview – Detection vs diagnosis: Irhythm and the Apple Watch
Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
ACC 2019 preview – Amarin and Esperion look for an edge
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
ACC 2019 preview – Medtronic seeks guidelines change with Tyrx data
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Bayer holds its nerve as patent cliff approaches
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.